FDA PCAC Peptide Meeting Explained: What It Means for Compounding Pharmacies (BPC-157, TB-500)
FDA / PCAC — official records & coverage — FDA PCAC Peptide Meeting Explained: What It Means for Compounding Pharmacies (BPC-157, TB-500)
Channel: ATRIUM24 · Our label: Government proceedings and coverage of them · Source: youtube.com/watch?v=PDJ0_OInrOY
What this video covers
Welcome to the webinar today inside the FDA peptide meeting. What actually happened and what it means for your pharmacy. We were really excited to dive into this topic. As you guys know, Dave was in the room, so we can’t wait to pick his brain and see what’s going on there.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- Um the other thing that really surprised me the most was the I thought the discussion was going to be entirely focusing on the clinical um studies and clinical aspect of it.
- Um, » and I think some of them were looking more towards um, you know, the differences between full FDA approval versus what the um, compounding list is.
- Um, and then I want to say FDA like returned to concerns regarding incomplete characterization, insufficient safety data, inconsistent naming conventions, and limited efficacy evidence.
- And I think committee members were the committee was trying to find a way to I guess alert the public that um not enough safety studies, not enough efficacy studies, um too much grain market.
- But on the other hand, like of course you know not much safety studies, not much efficacy, that does not mean you know those peptides are not safe.
- Uh a custom compounded medication is um » prescribed I would say recommended but prescribed for these patients.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.